Show simple item record

dc.contributor.advisorOlsvik, Ørjan
dc.contributor.authorHaug, Pål Juliussen
dc.contributor.authorBrochmann, Dag Jørgen Dybwad
dc.description.abstractBackground: African sleeping sickness is one of the World Health Organizations (WHO) defined neglected tropical diseases. It is endemic in 36 sub-Saharan Africa countries. Even though the incidence has decreased in all these countries the last decade, the incidence of infected travelers is increasing due to increased tourism. The disease is challenging to diagnose, and is regarded as fatal if left untreated. Material and methods: This is a literature review based on systematic search in PubMed. In addition cross-section surveys were carried out in Zanzibar (Tanzania), a former HAT-endemic island (n=50) and in Kasongo (the Democratic Republic of Congo, DRC), a current HAT-infected area (n=50). Clinical experience was obtained in different health care centers and hospitals in Kinshasa (DRC) and Kasongo (DRC). We interviewed people on all levels working with HAT. E.g the health minister of Maniema, the leader of the Belgium partner (BTC-CTB) and mobile team workers in Kinshasa, and remote Kasongo. Results and principal findings: Human African trypanosomiasis (HAT) still poses a major problem in the remote and poorest parts of Africa. The lack of vaccine and prophylaxis against HAT makes it even more important with sufficient prevention and control programs. The disease is caused by the parasite of the species Trypanosoma brucei. Its vector is the tsetse fly. The disease is divided into two stages, separated by whether trypanosomes are present in the central nervous system or not. The first stage presents a fever illness. The second stage presents several of neurological symptoms, such as sleeping disorder. The clinical feature alone is insufficient to set the diagnosis, and the diagnostic tools presented today do not show enough accuracy. The treatment of late stage HAT has severe side effects. The last 60 years has only seen one new drug for HAT. We found the awareness of HAT in Zanzibar to be limited to 30%. In Kasongo 78% of the population were found to have knowledge of HAT. Among those who had knowledge, only 32% knew that the tsetse fly was the transmitter. Conclusion: As the incidence of HAT is decreasing, so is the attention. HAT may well go from being a neglected disease to an ignored disease. Thus we cannot rule out the possibility of a new outbreak. To prevent an increase of HAT, or even a new epidemic, it is of great importance to maintain the prevention and control programs. The development of more specific diagnosis and staging tools is urgent. The Holy Grail will be the development of a vaccine, though there is still a long way to go.en
dc.publisherUniversitetet i Tromsøen
dc.publisherUniversity of Tromsøen
dc.rights.holderCopyright 2012 The Author(s)
dc.rightsAttribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Tropical medicine: 761en
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Communicable diseases: 776en
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Medical microbiology: 715en
dc.subjectAfrican sleeping sicknessen
dc.subjecttsetse flyen
dc.titleAfrican sleeping sickness in The Democratic Republic of Congo : on the edge of an outbreak?en
dc.typeMaster thesisen

File(s) in this item


This item appears in the following collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 Unported (CC BY-NC-SA 3.0)